Replies to post #120602 on Biotech Values

[ronpopeil]

But the failure of the AIM-HIGH study no longer makes it the drug of choice. AMR-101, still shows more of a benefit when you compare the two with all things being equal. Had AIM-HIGH been successful, then AMR-101 could have been viewed as somewhat inferior. That is no longer the case imo which is why you are seeing a positive reaction in the stock price. I still believe AMRN's outcomes study will be successful

[ronpopeil]

Go to medscape.org and search to article # 518574 to view the JELIS study